Drug class
BCMA-directed CD3 T-cell-engaging bispecific antibody; antineoplastic biologic
Mechanism of action
Binds B-cell maturation antigen (BCMA) on plasma cells and multiple myeloma cells and CD3 on T cells, bringing T cells into proximity with BCMA-expressing tumour cells and inducing T-cell-mediated cytolysis.
General use cases
- Treatment of adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, under the US product indication; current label and local authorisation criteria apply
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
